family with sequence similarity 133 member A pseudogeneGenealiases: []
Q-omics provides the consensus-scored FAM133GP profile across patient tissues and cancer cell-line models. FAM133GP expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FAM133GP is differentially expressed in 2, with the highest sampling consensus in LUAD. Additionally, FAM133GP RNA expression shows 8,978 significant gene co-expression associations, with the highest sampling consensus in LIHC. Together, these results highlight KIRC, LUAD, and LIHC as cancer lineages where FAM133GP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM133GP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM133GP survival associations across molecular data types. FAM133GP RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM133GP RNA expression–survival associations across cancer types. High FAM133GP expression shows unfavorable associations in KIRC, THYM, LIHC, SKCM and DLBC, but favorable associations in STAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FAM133GP RNA expression.
This table summarizes FAM133GP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for FAM133GP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM133GP shows lower tumor expression in LUAD and KICH. The LUAD box plot shows higher FAM133GP RNA expression in normal versus tumor tissue (log2 FC = −0.098, t-test p = .015).
This table shows molecular features associated with FAM133GP in patient tissues and cancer cell lines. In patient samples, FAM133GP shows the broadest associations at the RNA and protein expression levels, with LIHC recurring as the lineage with the largest associated feature set.
